This randomized, controlled study compared the ability to mobilize and collect an optimal target yield of 5 × 10 6
During the 1990s, peripheral blood largely replaced bone marrow (BM) as the stem cell source for autologous transplantation after high-dose myeloablative chemotherapy with or without radiotherapy in cancer patients. [1] [2] [3] Using chemotherapy agents and/or cytokines, it has been possible to mobilize hematopoietic stem and progenitor cells from the bone marrow to the peripheral blood in numbers sufficient for harvesting (by leukapheresis) and transplantation.
1,2,4-6 Transplantation of peripheral blood progenitor cells (PBPC) has also been shown to provide faster rates of engraftment than transplantation of BM. [1] [2] [3] With the emergence of PBPC mobilization, methods for quantitation of desired cells have been developed. Currently, the number of CD34 + cells in the harvest is considered the best predictor of neutrophil and platelet engraftment after transplantation. 3, 4, [7] [8] [9] [10] [11] [12] [13] As the methodologies for quantitation of CD34 + cells have been standardized, 7, 14 various investigators have suggested that у5 × 10 6 CD34 + cells/kg is an appropriate target for transplantation because it enables nearly all patients to engraft quickly. Conversely, transplantation of less than 1 to 2 × 10 6 CD34 + cells/kg is associated with delayed engraftment, especially of platelets, or engraftment failure in up to 20% of patients. 3, [8] [9] [10] [11] [12] [13] 15 Because leukapheresis has associated morbidities, complications and costs, it is desirable to maximize the efficiency of CD34 + cell mobilization and thereby minimize the number of leukaphereses required to collect an optimal number of cells. Filgrastim (recombinant G-CSF) and sargramostim (recombinant GM-CSF) are approved for CD34 + cell mobilization. 1, 2, 4, 16 Other cytokines in combination with filgrastim have been studied for potential enhancement of mobilization, including recombinant human stem cell factor (SCF, ancestim); 15, [17] [18] [19] [20] [21] recombinant human Mpl ligands; 22, 23 flt-3 ligand; 24 and interleukin-3 receptor ligands. 25 SCF is an early-acting hematopoietic factor which displays pronounced synergies with other, later-acting hematopoietic factors, both in vitro and in vivo, to promote growth and maturation of primitive progenitors. [26] [27] [28] Preclinical studies in rodent, dog, and baboon models have shown that administration of species-specific SCFs in combination with G-CSF, when compared with administration of G-CSF alone, markedly enhances the mobilization of PBPC capable of rapid short-term and long-term hematopoietic engraftment after harvesting and transplantation in myeloablated recipients. [29] [30] [31] [32] [33] [34] Various parameters have been reported to influence the ability to mobilize CD34 + cells. These include tumor type and type of mobilization regimen used (eg chemotherapy and/or cytokines). Age, disease involvement in the bone marrow, prior chemotherapy, and prior radiotherapy have a negative impact on mobilization efficiency, with the latter two factors reported most consistently. 3, 4, 8, 35 The study reported here prospectively utilized these factors in defining hard-to-mobilize lymphoma patients, and evaluated the ability of SCF plus filgrastim, compared with filgrastim alone, to mobilize CD34 + cells in this heavily pretreated patient population.
Patients and methods

Patients
This study was conducted in heavily pretreated patients with histologically or morphologically confirmed Hodgkin's disease (HD) or NHL. Patients with HD were in first or second relapse post chemotherapy or had failed to enter a complete remission (CR) with initial chemotherapy. Patients with NHL were enrolled in first remission, if they met criteria for heavy prior therapy as outlined below, or had evidence of chemosensitive, relapsed disease. Patients were defined as heavily pretreated based on having received at least two cycles of procarbazine, nitrogen mustard, nitrosoureas (including BCNU), or melphalan; high-dose Ara-C (total у7 g); у10 cycles of any chemotherapy; or radiation to the mediastinum, abdomen, or pelvis (excluding spot radiation to non-BM-containing sites).
Eligibility criteria also included age 18-65 years; Karnofsky performance status greater than 80%; life expectancy greater than 6 months; absolute neutrophil count (ANC) у2.0 × 10 9 /l; platelet count у100 × 10 9 /l; and hemoglobin (Hb) у9 g/dl.
Among the exclusion criteria were histologic evidence of lymphoma in the BM or central nervous system involvement; other malignancies within the preceding 5 years; prior BM or PBPC transplantation; and history of asthma or severe allergy. Human Investigation Review Committeeapproved written informed consent was obtained for all patients.
Study design
The study was divided into three parts: collection phase, treatment phase, and follow-up phase (Figure 1 ).
Collection phase
Patients were randomized 1:1 to receive subcutaneous injections of filgrastim (10 g/kg/day) in combination with SCF (20 g/kg/day) or Filgrastim alone (10 g/kg/day) for 5-9 days. Treatment with SCF was accompanied by a three-drug premedication regimen of ranitidine, albuterol, and either diphenhydramine or cetirizine, to decrease the mast cell-mediated side-effects of the drug. [26] [27] [28] Cytokine injections began on day 1 of the collection phase and were repeated daily until the completion of the leukaphereses. Leukapheresis (10 liters per day) began on day 5, and continued until the cumulative CD34 + cell yield in the leukapheresis harvests was у5 × 10 6 /kg or until day 9, whichever came first (ie a maximum of five leukaphereses were allowed on this study). Patients whose cumulative CD34 + cell yields with the five leukaphereses were less than 1 × 10 6 /kg, the minimum considered acceptable for transplant, were withdrawn from the study, and were treated as per each center's standard management for non-mobilizing patients.
Treatment phase
Following a rest period of 3 to 14 days, patients received one of three myeloablative conditioning regimens: TBI, cyclophosphamide, and etoposide; 36 busulfan, melphalan and thiotepa (BuMelT); 37 or cyclophosphamide, BCNU, and etoposide (CBV). 38 Patients who had received prior dose-limiting radiation were treated with either BuMelT or CBV. Patients were then infused with their total collected PBPC, beginning on day 0 of the treatment phase. For both treatment groups, post-transplant filgrastim support (10 g/kg/day) began on day 0 and was continued until the ANC was у5 × 10 9 /l for 3 days or у10 × 10 9 /l for 1 day. SCF was not administered post-transplant in any patients. RBC transfusions were given for Hb Ͻ8 g/dl, and platelet transfusions for platelets Ͻ10 × 10 9 /l. Platelet engraftment was defined as у20 × 10 9 platelets/l for 3 consecutive days without transfusions, and the treatment phase was complete when patients achieved у50 × 10 9 platelets/l independent of transfusions.
Follow-up phase
Patients were seen at 60 and 100 days after PBPC infusion to assess the long-term durability of engraftment, disease status, and survival.
Progenitor cell assay
The CD34
+ cell quantitation was performed at a central laboratory (Cytometry Associates Inc, San Diego, CA, USA) by flow cytometry, as described previously. 15, 21 The central laboratory was blinded to patient treatment group assignment.
Statistical analyses for efficacy
The study sample size was chosen with the expectation of a PBPC collection difference between the two treatment groups of 0.25 × 10 6 CD34 + cells/kg per leukapheresis (first day values) using a pooled standard deviation of 0.42 × 10 6 /kg. To detect this difference at the 5% level with an 80% power would require 45 evaluable patients per treatment group. Efficacy analyses were performed both on modified intent-to-treat (as specified in the study protocol) and on efficacy-evaluable patient groups. For each of these patient groups, the collection and treatment phases were analyzed separately. For the collection phase, the intent-totreat analysis included all patients who received cytokine therapy and for whom at least one leukapheresis CD34 + cell yield value was available, while the efficacy-evaluable patient group differed in that patients with protocol violations (ie non-compliance with the protocol that could have significantly impacted the study endpoints) were excluded. For the treatment phase, the intent-to-treat analysis included all patients who received their PBPC infusion. Patients were excluded from the efficacy-evaluable analyses for the treatment phase if there were protocol violations during this phase of the study, or if they had been excluded from the efficacy-evaluable analyses for the collection phase. Both in the collection phase and in the treatment phase, the primary patient group for study analyses was the intent-to-treat group. All data presented are for the intentto-treat patient group unless otherwise noted.
Summary statistics were calculated by treatment group for the number of CD34 + cells/kg collected on the first day of leukapheresis, the number collected on subsequent days of leukapheresis, the number collected per leukapheresis, and the total collected for all days of leukapheresis. The Wilcoxon rank sum test was used when comparing groups with regard to daily leukapheresis CD34 + cell yields. Numbers and proportions of patients reaching cumulative yields of у1 × 10 6 CD34 + cells/kg (the minimum yield) and of у5 × 10 6 CD34 + cells/kg (the target yield) within five leukaphereses were determined. Greenwood's z-test 39 on Kaplan-Meier estimates was used when comparing treatment groups for differences in the proportion of patients who reached a target within five leukaphereses. Summary statistics were also calculated from the Kaplan-Meier estimates within each treatment group for the number of leukaphereses required to reach 5 × 10 6 CD34 + cells/kg. Analy-
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ses of the number of leukaphereses were performed using Cox proportional hazards regression. Time to engraftment (number of days to recover ANC у0.5 × 10 9 /l and у20 × 10 9 platelets/l) were also summarized by treatment group using Kaplan-Meier estimates and event-free survival curves. Comparisons between treatment groups were made using the generalized Wilcoxon test for event-free survival data.
The number of RBC and platelet transfusions post transplant were summarized by treatment group. Comparisons between treatment groups were performed using the Wilcoxon rank sum test.
All hypothesis testing and confidence interval estimates were two-sided and performed at the 5% significance level. All analyses were conducted using SAS version 6.11 (SAS Institute Inc, Cary, NC, USA) on a Sun Sparc Station running under UNIX.
Safety data collection
In the collection phase, the safety profiles were assessed by treatment group through evaluation of adverse events, laboratory data (hematology and chemistry), and vital signs. All patients who received at least one dose of study drug were included in the safety analyses for the collection phase. All patients receiving myeloablative therapy were included in the safety analyses for the treatment phase. Adverse events during hospitalization post transplant were captured and, after discharge from the hospital, serious adverse events to day 60 post transplant, and deaths to day 100 post transplant, were captured.
Study drug
SCF (recombinant methionyl human stem cell factor; ancestim) and filgrastim (recombinant methionyl human granulocyte colony-stimulating factor; Neupogen) were supplied by Amgen, Inc (Thousand Oaks, CA, USA).
Results
Patient profile
Demographic and baseline characteristics: One hundred and seven patients with NHL or HD were randomized to receive treatment at the 14 participating centers. The demographic and baseline characteristics for the randomized patients are provided in Table 1 . The majority of patients were Caucasian (82%) and male (63%); patient age ranged from 20 to 65 years (median 44 years). The two treatment groups were evenly balanced for age, sex, race, weight, and baseline hematology and disease characteristics.
Criteria for extensive prior therapy: Ninety-seven percent (104/107) of randomized patients met at least one of the criteria defining heavy pretreatment (Table 2 ). In the SCF 
18 (35) 22 (39) 16 (48) 19 (50) 2 (11) 3 (17) 2 13 (26) 22 (39) 9 (27) 14 (37) 4 (22) 8 (44) у3 19 (37) 10 (18) 7 (21) 3 (8) 12 (67) 7 (39) plus filgrastim group, 37% of the patients met у3 criteria compared with 18% in the filgrastim alone group. This trend was irrespective of disease type. The two treatment groups were evenly balanced with respect to each of the specific heavy pretreatment criteria with the exception of prior radiation (radiation to the mediastinum, abdomen, or pelvis) (Table 3 ). More patients randomized to receive SCF plus filgrastim had prior radiotherapy than did patients randomized to receive filgrastim alone (45% vs 18%).
Collection phase efficacy data
A total of 102 patients with HD or NHL underwent at least one leukapheresis and were included in the modified intentto-treat efficacy analyses (48 in the SCF plus filgrastim group and 54 in the filgrastim alone group). Of the 5/107 randomized patients who did not undergo any leukapheresis and were therefore not included in the intent-to-treat patient group, three had been randomized to the SCF plus filgrastim group. Of these three, one was withdrawn because of disease progression, and one was withdrawn as per request (neither received any cytokines); the third was withdrawn 475 Table 3 Cumulative number and proportion of patients reaching the target CD34 + cell yield of 5. because of an allergic-like reaction on day 4 of cytokine administration that was reported as related to SCF. The other two patients had been randomized to the filgrastim alone group; reasons for withdrawal were disease progression and central line complications. Several patients, upon review, did not meet ANC/platelet count minimum values for enrollment. However, their values were essentially at the lower limits, and their mobilizations were similar to those of the larger group. They were therefore included in all analyses. There were protocol violations in 10 patients during the collection phase which could affect the results of the study. Three, as noted above, did not meet criteria for heavy prior therapy; one had progression of disease; one had collections aborted for poor yield (control group); and the remaining five had technical deviations including too small a volume collected or CD34 + cell samples not available for testing. Excluding these 10, 92 patients comprised the efficacy-evaluable patient group for this phase (45 in the SCF plus filgrastim group and 47 in the filgrastim alone group). Results are reported for all 102 patients (the intent-to-treat group); results for the efficacy-evaluable patient group were essentially identical to those for the intent-to-treat group, unless otherwise noted. A total of 105 patients with NHL or HD received at least one dose of cytokine and were included in the safety analyses for the collection phase (49 in the SCF plus filgrastim group and 56 in the filgrastim alone group).
Number of CD34
+ cells collected: The median yield of CD34 + cells per leukapheresis was higher for the SCF plus filgrastim group (0.73 × 10 6 /kg) than for the filgrastim alone group (0.48 ×x 10 6 /kg) (P = 0.04). In addition, the median total CD34
+ cells collected within five leukaphereses was higher for the SCF plus filgrastim group (3.6 × 10 + cells on leukapheresis days 2 to 5, compared with patients receiving filgrastim alone. The differences were statistically significant (P Ͻ 0.05) for leukapheresis days 3, 4, and 5. There were decreases in the daily median numbers of CD34 + cells/kg collected over time in both treatment groups. (Note that patients reaching the target on any given day did not undergo leukapheresis on subsequent days; the number of patients remaining after each day of leukaphereses is indicated beneath the graph in Figure 2 .) The rate of decline in cell yield over multiple leukapheresis days was markedly slower in the SCF plus filgrastim group. By the 5th day of leukapheresis, CD34
+ cell yields had fallen to approximately 65% of the day 1 yields for the SCF plus filgrastim group, compared with 30% of the day 1 yields for the filgrastim alone group, demonstrating a more sustained CD34 + cell yield with the cytokine combination treatment. + cells/kg on each leukapheresis day is presented in Table 3 . The percentage of patients reaching the target within five leukaphereses was significantly higher in the SCF plus filgrastim group (44%) than in the filgrastim alone group (17%) (P = 0.002). Patients who received SCF plus filgrastim had four to five times greater odds of reaching the target across the days of leukapheresis. There was a tendency toward fewer patients who received SCF plus filgrastim failing to yield the minimum number of CD34 + cells to allow transplantation (1 × 10 6 /kg). Sixteen percent of patients in the SCF plus filgrastim group failed to yield this minimum number within five leukaphereses, compared with 26% of patients in the filgrastim alone group (P = 0.21). The corresponding values for the efficacy-evaluable patient group were 11% and 23%, respectively (P = 0.11).
Proportion of patients reaching
Number of leukaphereses required to reach 5 × 10
6 CD34 4 cells/kg: Fewer than 50% of patients in each treatment group achieved the target yield within the five scheduled leukaphereses; therefore the median number of leukaphereses required to reach the target was у6 for each group. Nevertheless, there was a significant reduction in the number of leukaphereses required to reach the target yield of 5 × 10 6 CD34 + cells/kg in the SCF plus filgrastim group compared with the Filgrastim group alone (P = 0.003).
Treatment phase efficacy data
For the treatment phase, 76 patients received their PBPC infusion and were included in the intent-to-treat efficacy analyses (37 in the SCF plus filgrastim group and 39 in the filgrastim alone group). Twenty-five patients did not proceed to the treatment phase. Of these, 22/25 were unable to do so because of low CD34 + cell yields (8 (16%) in the SCF plus filgrastim group; 14 (26%) in the filgrastim alone group, not statistically significant). The others did not proceed because of disease progression (1 (2%) in the SCF plus filgrastim group; 2 (4%) in the filgrastim alone group). One additional patient in the filgrastim alone group who proceeded to the treatment phase was withdrawn due to disease progression before undergoing transplant, and was not included in the treatment phase intent-to-treat patient group.
Among the 37 patients in the SCF plus filgrastim group who received a conditioning chemotherapy regimen after mobilization/leukapheresis, 15 (41%) received TBI, cyclophosphamide, and etoposide; 6 (18%) received BuMeIT; and 15 (41%) received CBV (one patient received a regimen not listed in the protocol, ie thiotepa, cyclophosphamide, and etoposide). Among the 39 patients in the filgrastim alone group, the corresponding numbers were 19 (49%), 8 (21%), and 12 (31%). Thus the distribution of patients receiving the various conditioning regimens was similar for the two mobilization groups.
Eight patients had one or more protocol violations during the treatment phase. These violations included deviations in post-transplant filgrastim administration (four), delays in initiating transplant therapy (three), ineligible preparative regimens (two), and failure to administer all leukapheresis products (one). When these eight protocol violators were excluded, 68 patients comprised the efficacy-evaluable patient group for this phase (35 in the SCF plus filgrastim group and 33 in the filgrastim alone group). As noted below, no differences in engraftment were noted for the intent-to-treat and efficacy-evaluable group.
Hematologic recovery:
The median time to ANC у0.5 × 10 9 /l was 10 days for both treatment groups (Figure 3) . Although the slight shift in time to ANC recovery seen in Figure 3 was statistically significant (P = 0.02), the was no difference in the more clinically relevant parameter of days with ANC Ͻ0.5 × 10 9 /l (median 9 days in both groups, P = 0.68). The median time to у20 × 10 9 platelets/l was 12 days for both groups (Figure 3 ). There were no significant differences between the two treatment groups in the requirements for RBC transfusions (median two in each group) and platelet transfusions (median four in each group). Similar engraftment results were noted for the efficacy-evaluable patient group.
Engraftment failures by day 14 or day 28:
Data from the current study support у5 × 10 6 CD34 + cells/kg as an optimal mobilization yield to ensure rapid platelet engraftment post transplant. The proportion of patients who failed to engraft to platelets у20 × 10 9 /l by day 14 and by day 28 was related to the CD34 + cell dose (Figure 4) . Patients who received у5 × 10 6 CD34 + cells/kg were less likely to fail to engraft platelets by day 14 and by day 28 than those who did not receive this dose. These results are similar to those estimated from the Cox proportional hazards model of this study ( Figure 5 ). Based on this model, with a CD34 + cell yield of 5 × 10 6 /kg, the estimated probabilities of engraftment to у20 × 10 9 platelets/l by day 14 and by day 28 were 79% and 98%, respectively. However, with a CD34 + cell yield of 2 × 10 6 /kg, the predicted probabilities of engraftment by day 14 and by day 28 were only 58% and 88%, respectively. 
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Safety data
Collection phase adverse events: During the collection phase, all patients randomized to the SCF plus filgrastim group received a three-drug premedication regimen of ranitidine, albuterol, and either diphenhydramine or cetirizine because of the potential for mast cell-mediated reactions observed with SCF administration. The majority of adverse events reported during the collection phase were mild to moderate in severity for both treatment groups.
The incidence of patients experiencing at least one adverse event, regardless of relationship to study drug, was similar for both treatment groups (SCF plus filgrastim group, 94%; filgrastim alone group, 84%). Injection site reactions, thought to be the result of local mast cell degranulation, 40 were the most frequently reported adverse events in the SCF plus filgrastim group, occurring in 84% of patients. These reactions were mild to moderate in severity; were primarily injection site erythema (59%), pruritus (24%) and urticaria (18%); and generally occurred within 24 h after the SCF injection and spontaneously resolved within 24 to 48 h.
Consistent with the known side-effects of filgrastim, musculoskeletal symptoms, primarily skeletal pain, back pain and arthralgia were reported as at least possibly related to cytokine in 31% of patients treated with SCF plus filgrastim and in 30% of the patients treated with filgrastim alone.
Non-serious respiratory events reported as at least possibly related to cytokine occurred in three patients treated with SCF plus filgrastim and one patient treated with filgrastim alone. The three SCF plus filgrastim events were intermittent (over 4 days) mild dyspnea and cough, treated with additional albuterol; mild sore throat (1 day duration) which resolved without treatment; and a transient episode of moderate dyspnea and throat tightness that resolved without treatment. The one filgrastim alone event included cold and flu symptoms (upper respiratory infection) which occurred on days 4 to 7 of cytokine administration (treated with tylenol).
Serious adverse events during the collection phase occurred in six patients (13%) in the SCF plus filgrastim treatment group and five patients (9%) in the filgrastim alone treatment group. In the SCF plus filgrastim treatment group, one patient died due to complications of progressive disease considered unrelated to SCF and five patients experienced systemic allergic-like reactions that were considered at least probably related to SCF. These reactions occurred several hours after the fifth or sixth SCF injection in four patients and 5 min after the fourth injection in one patient; none of the reactions was life-threatening. One patient experienced generalized urticaria only; three patients experienced urticaria and respiratory symptoms (primarily throat tightness); and one patient experienced respiratory symptoms only (dyspnea, wheezing and cough), 5 min after the fourth injection. Symptoms in all five patients resolved within 30 min to 4 h after treatment with additional antihistamines and/or steroids. No patient received epinephrine. In the filgrastim alone group, two of the serious adverse events (superior vena cava syndrome in one patient and pancreatitis in the other) were related to progressive disease and three were related to central line complications including thrombosis and/or bacteremia.
Collection phase laboratory results:
During the collection phase, peripheral WBC counts increased in both treatment groups, as would be expected. Only one patient (combination group) had a WBC Ͼ100 x 10 9 /l. This patient's WBC count was 27.9 × 10 9 /l at baseline, and increased to 114.5 × 10 9 /l on day 4 of the collection phase. The dose of filgrastim was reduced to 1 g/kg, and by the subsequent day the WBC had decreased to 84.7 × 10 9 /l. The patient's total CD34 + cell yield (two leukaphereses) was 5.02 × 10 6 /kg. There were no clinical sequelae associated with any level of leukocytosis in any of the patients.
Median values for lactate dehydrogenase (LDH) and uric acid were higher in the SCF plus filgrastim group than in the filgrastim alone group. These elevations probably resulted from increased cell production and turnover, as reported previously with filgrastim, 41 and may have been augmented with the addition of SCF. None of the elevations was considered to be clinically significant.
Treatment phase adverse events: Seventy-seven patients proceeded from the collection phase to the treatment phase and were included in the safety analysis for the treatment phase (note that one of the 77 patients received myeloablative therapy, and was therefore included in the safety analysis, but did not undergo PBPC transplantation and was excluded from efficacy analyses). Of these 77 patients, 15 (SCF plus filgrastim group, 8; filgrastim alone group, 7) had serious non-fatal adverse events within 60 days after transplant, and seven (SCF plus filgrastim group, 5; filgrastim alone group, 2) died within 100 days after transplant. These events were associated with high-dose chemotherapy or progressive disease and none were reported as related to SCF or filgrastim.
Discussion
While lymphoma patients have a potential for remission or cure with high-dose therapy, [42] [43] [44] [45] a significant number will have delayed hematopoietic engraftment due to suboptimal PBPC doses administered after ablative therapy. Recent data suggest a dose-response relationship between the number of CD34
+ cells infused and engraftment kinetics, especially for platelet recovery. 3, 4, [7] [8] [9] [10] [11] [12] [13] /kg have been associated with a high frequency of rapid platelet recovery 3, [8] [9] [10] 15, 21 and therefore are considered optimal. The benefits of CD34 + cell doses у5 × 10 6 /kg in terms of enhanced engraftment kinetics are confirmed by data in the present report. Enhanced engraftment kinetics in turn translate into a reduction in the frequency of infections and other complications associated with post chemoradiotherapy neutropenia and thrombocytopenia, and reduction in the need for RBC and platelet transfusions, antibiotic use, hospitalization, and growth factor support. 53, 54 While CD34
+ doses of у5 × 10 6 cells/kg may be considered optimal, this level is difficult to achieve in many patients. The CD34 + cell yield has been shown to be adversely affected by a number of factors, including the type of chemotherapy received prior to mobilization (eg stem cell toxic chemotherapies such as BCNU or melphalan); extensive (amount and/or duration) prior chemotherapy; extensive prior radiotherapy to the pelvis and sternum; age; and tumor cell infiltration to the bone marrow. 3, 4, 8, 9, 17, 38, 50, [55] [56] [57] The present study focused on prior chemoradiotherapy. It was designed to assess the efficacy of the cytokine combination of SCF plus filgrastim vs the efficacy of filgrastim alone in enabling the mobilization and harvesting of an optimal number of CD34 + cells in NHL patients prospectively defined as heavily pretreated with chemoradiotherapy. The definition of extensive prior therapy used prospectively in this study clearly selected for patients who mobilized poorly with filgrastim alone, since approximately a quarter of patients in the filgrastim alone group failed to reach 1 × 10 6 CD34 + cells/kg and only 17% attained an optimal yield of у5 × 10 6 CD34 + cells/kg. In addition, total yields were lower than those seen in less heavily pretreated patients. 21 Therefore this study validates, at least to some extent, the criteria proposed by Moskowitz et al. 17, 35 To date, the combination of SCF plus filgrastim is the only strategy proven to increase PBPC yields in the heavily pre-treated patient, while reducing the number of leukaphereses required to collect a given number of cells. Similar mobilization enhancement results with SCF have previously been reported in patients with other cancers, 15, 18, 20, 21 and in another study of patients with NHL. 17 While collection of 2 × 10 6 CD34 + cells/kg was not an endpoint of the study, the combination of SCF and filgrastim also increased the proportion of patients reaching this intermediate target. For the combination group, 70% of patients reached this target in five leukaphereses, compared with 54% for the filgrastim alone group. If the target of the 2 × 10 6 CD34 + cells/kg was considered the target cell dose in this study, 46% of the patients in the filgrastim alone group, but only 30% in the SCF combination group would be considered mobilization failures.
The increased total CD34 + cell yields with SCF plus filgrastim reflect the fact that mobilization was more sustained over time than with filgrastim alone, ie the decline in yield with repeated leukaphereses was less steep. In this study, the median CD34 + cells/kg harvested on day 5 of leukapheresis for the filgrastim group alone was about 25% of that on day 1, while for the SCF plus filgrastim group, the median day 5 collection was about 65% of that of day 1 yields. Similar observations were made in a study of breast cancer patients, 21 and for poor mobilizers, suggests that additional leukaphereses, beyond five, might yield sufficient cells for transplantation, rather than the need to re-mobilize or to harvest bone marrow.
The increase in CD34 + cell yields resulted in a reduced number of leukaphereses required to reach the optimal CD34 + cell target, with 85% of the patients in the filgrastim group vs only 60% in the SCF plus filgrastim group requiring all five leukaphereses. In a clinical trial in breast cancer patients, those patients receiving the combination of SCF plus filgrastim reached the optimal yield with a median of four leukaphereses, whereas those receiving filgrastim alone required a median of у6 leukaphereses. 21 Thus, the results of this and previous 15, [17] [18] [19] [20] [21] clinical studies suggest that the use of SCF along with filgrastim for mobilization can be expected to benefit transplant patients in various ways. It can be expected that 'poor' mobilizers with filgrastim alone (Ͻ1.0 × 10 6 CD34 + cells/kg) would be more likely to reach a minimum yield (1-2 × 10 6 CD34 + cells/kg) with a reasonable number of leukaphereses, enabling a safe transplant and avoiding treatment delays and the need for re-mobilization or bone marrow harvesting. 'Moderate' mobilizers with filgrastim alone (2-5 × 10 6 CD34 + cells/kg) would be more likely to reach an optimal yield (5 × 10 6 CD34 + cells/kg), and 'good' mobilizers with filgrastim alone (у5 × 10 6 CD34 + cells/kg) may reach an optimal yield with fewer leukaphereses. Reducing the number of leukapheresis procedures is beneficial for reasons such as increased patient convenience; reduced cost (estimated cost is US $2266 per leukapheresis 58 ); and reduced morbidity. Morbidities associated with extended leukapheresis include transient symptomatic hypotension and anticoagulant-related symptomatic hypocalcemia. 59 In addition, and especially important for patients with lymphoma, in at least one series, 4% of patients had disease progression during time delays associated with extended PBPC collection periods. 59 Another potential benefit of the enhanced mobilization seen with the cytokine combination is the potential elimination of the need for chemotherapy/ cytokine mobilizations for this patient group, and the associated morbidities and cost.
Neutrophil engraftment and platelet engraftment in this study were similar between treatment groups. These results are expected because patients in each group were mobilized to the same target CD34 + cell yield, because there was a broad overall spread in the total CD34 + cell collection within each treatment group, and because the protocol required that patients with CD34
+ cell yields of less than 1 × 10 6 /kg not continue on study (16% in the SCF plus filgrastim group vs 26% in the filgrastim alone group).
In this and other clinical studies of SCF, patients have been screened for allergies and received premedication, and treatment with SCF has been safe and generally well tolerated. The only potentially serious adverse events associated with SCF are systemic allergic-like reactions that were not life-threatening. In other published PBPC mobilization studies using SCF, the incidence of such reactions has been 2/147 (1.4%), 15 0/26 (0%), 17 1/36 (2.8%), 18 1/44 (2.3%), 20 3/100 (3%), 21 1/13 (8%), 60 and 0/55 (0%). 61 The incidence in the present study was 5/48 (10%); this relatively high value probably represents random variation in the occurrence of this low-frequency event.
In conclusion, based on the increased proportion of patients reaching target yields of PBPC and reduction in the number of leukaphereses required, SCF plus filgrastim can be considered an important mobilization option for heavily pretreated Hodgkin's disease and non-Hodgkin's lymphoma patients receiving ablative therapy with PBPC support.
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